Pharmaceutical economics and policy:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Oxford
Oxford University Press
2007
|
| Ausgabe: | 2nd ed |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | Includes bibliographical references and index The pharmaceutical industry -- The biotechnology industry -- Other firms in the pharmaceutical industry -- Marketing pharmaceuticals -- The demand for pharmaceuticals -- Pharmaceutical prices -- The worldwide market for pharmaceuticals -- Pricing pharmaceuticals in a world environment -- The timing of drug approvals in the United States and abroad -- Pharmaceutical regulation and cost containment by the public sector -- Regulation by the private sector -- Pharmaceutical regulation in Europe -- Patent protection -- Evaluating New Drugs -- Complementary and alternative medicines -- Pharmaceuticals and health policy : a look ahead The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its apparent anticompetitive responses to generic competition. Even its research and development priorities are criticized as being too closely driven by the goal of maximizing shareholder value, rather than the health of the public. Unfortunately, many of the critics of the industry fail to understand the complexities of the industry and its role in the nation's healthcare system. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This is the second edition of a uniquely comprehensive and balanced discussion of pharmaceutical policy issues. All the chapters of the former edition have been fully re-written and extensively updated. In addition, the book includes six new chapters on emerging topics such as the broadened role of FDA regulations and the increasing diversity of the industry. An entire chapter is devoted to the biotechnology industry and one to alternative medicines, often called "nutraceuticals." Another new chapter discusses segments of the industry that specialize in particular activities including generic drugs and drug delivery systems. The recent controversial expansion of Medicare to cover outpatient drugs is discussed in depth. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care |
| Beschreibung: | 1 Online-Ressource (xiv, 336 pages) |
| ISBN: | 9780199719747 0199719748 0195300955 9780195300956 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV042965407 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151030s2007 |||| o||u| ||||||eng d | ||
| 020 | |a 9780199719747 |c electronic bk. |9 978-0-19-971974-7 | ||
| 020 | |a 0199719748 |c electronic bk. |9 0-19-971974-8 | ||
| 020 | |a 0195300955 |9 0-19-530095-5 | ||
| 020 | |a 9780195300956 |9 978-0-19-530095-6 | ||
| 035 | |a (OCoLC)710992761 | ||
| 035 | |a (DE-599)BVBBV042965407 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 338.4/761510973 |2 22 | |
| 100 | 1 | |a Schweitzer, Stuart O. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Pharmaceutical economics and policy |c Stuart O. Schweitzer |
| 250 | |a 2nd ed | ||
| 264 | 1 | |a Oxford |b Oxford University Press |c 2007 | |
| 300 | |a 1 Online-Ressource (xiv, 336 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a The pharmaceutical industry -- The biotechnology industry -- Other firms in the pharmaceutical industry -- Marketing pharmaceuticals -- The demand for pharmaceuticals -- Pharmaceutical prices -- The worldwide market for pharmaceuticals -- Pricing pharmaceuticals in a world environment -- The timing of drug approvals in the United States and abroad -- Pharmaceutical regulation and cost containment by the public sector -- Regulation by the private sector -- Pharmaceutical regulation in Europe -- Patent protection -- Evaluating New Drugs -- Complementary and alternative medicines -- Pharmaceuticals and health policy : a look ahead | ||
| 500 | |a The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its apparent anticompetitive responses to generic competition. Even its research and development priorities are criticized as being too closely driven by the goal of maximizing shareholder value, rather than the health of the public. Unfortunately, many of the critics of the industry fail to understand the complexities of the industry and its role in the nation's healthcare system. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This is the second edition of a uniquely comprehensive and balanced discussion of pharmaceutical policy issues. All the chapters of the former edition have been fully re-written and extensively updated. In addition, the book includes six new chapters on emerging topics such as the broadened role of FDA regulations and the increasing diversity of the industry. An entire chapter is devoted to the biotechnology industry and one to alternative medicines, often called "nutraceuticals." Another new chapter discusses segments of the industry that specialize in particular activities including generic drugs and drug delivery systems. The recent controversial expansion of Medicare to cover outpatient drugs is discussed in depth. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care | ||
| 650 | 4 | |a Industrie pharmaceutique / États-Unis | |
| 650 | 4 | |a Médicaments / Politique gouvernementale / États-Unis | |
| 650 | 4 | |a Industrie pharmaceutique | |
| 650 | 7 | |a BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology |2 bisacsh | |
| 650 | 7 | |a Pharmaceutical industry |2 fast | |
| 650 | 7 | |a Pharmaceutical policy |2 fast | |
| 650 | 4 | |a Economics, Pharmaceutical / United States | |
| 650 | 4 | |a Drug Industry / United States | |
| 650 | 4 | |a Public Policy / United States | |
| 650 | 4 | |a Industrie | |
| 650 | 4 | |a Wirtschaft | |
| 650 | 4 | |a Pharmaceutical industry |z United States | |
| 650 | 4 | |a Pharmaceutical policy |z United States | |
| 650 | 4 | |a Pharmaceutical industry | |
| 650 | 0 | 7 | |a Internationaler Vergleich |0 (DE-588)4120509-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelmarkt |0 (DE-588)4003131-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Strukturwandel |0 (DE-588)4058136-6 |2 gnd |9 rswk-swf |
| 651 | 4 | |a USA | |
| 651 | 7 | |a USA |0 (DE-588)4078704-7 |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
| 689 | 0 | 1 | |a Arzneimittelmarkt |0 (DE-588)4003131-7 |D s |
| 689 | 0 | 2 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 689 | 1 | 0 | |a USA |0 (DE-588)4078704-7 |D g |
| 689 | 1 | 1 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 1 | 2 | |a Strukturwandel |0 (DE-588)4058136-6 |D s |
| 689 | 1 | |8 2\p |5 DE-604 | |
| 689 | 2 | 0 | |a Pharmazeutische Industrie |0 (DE-588)4045696-1 |D s |
| 689 | 2 | 1 | |a Gesundheitspolitik |0 (DE-588)4113743-7 |D s |
| 689 | 2 | 2 | |a Internationaler Vergleich |0 (DE-588)4120509-1 |D s |
| 689 | 2 | |8 3\p |5 DE-604 | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=191561 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBU | ||
| 940 | 1 | |q FLA_PDA_EBU | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028391275 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
Datensatz im Suchindex
| _version_ | 1804175290798178304 |
|---|---|
| any_adam_object | |
| author | Schweitzer, Stuart O. |
| author_facet | Schweitzer, Stuart O. |
| author_role | aut |
| author_sort | Schweitzer, Stuart O. |
| author_variant | s o s so sos |
| building | Verbundindex |
| bvnumber | BV042965407 |
| collection | ZDB-4-EBU |
| ctrlnum | (OCoLC)710992761 (DE-599)BVBBV042965407 |
| dewey-full | 338.4/761510973 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/761510973 |
| dewey-search | 338.4/761510973 |
| dewey-sort | 3338.4 9761510973 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| edition | 2nd ed |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05593nmm a2200805zc 4500</leader><controlfield tag="001">BV042965407</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151030s2007 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780199719747</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-19-971974-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0199719748</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-19-971974-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0195300955</subfield><subfield code="9">0-19-530095-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780195300956</subfield><subfield code="9">978-0-19-530095-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)710992761</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV042965407</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/761510973</subfield><subfield code="2">22</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schweitzer, Stuart O.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmaceutical economics and policy</subfield><subfield code="c">Stuart O. Schweitzer</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2nd ed</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford</subfield><subfield code="b">Oxford University Press</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xiv, 336 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">The pharmaceutical industry -- The biotechnology industry -- Other firms in the pharmaceutical industry -- Marketing pharmaceuticals -- The demand for pharmaceuticals -- Pharmaceutical prices -- The worldwide market for pharmaceuticals -- Pricing pharmaceuticals in a world environment -- The timing of drug approvals in the United States and abroad -- Pharmaceutical regulation and cost containment by the public sector -- Regulation by the private sector -- Pharmaceutical regulation in Europe -- Patent protection -- Evaluating New Drugs -- Complementary and alternative medicines -- Pharmaceuticals and health policy : a look ahead</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its apparent anticompetitive responses to generic competition. Even its research and development priorities are criticized as being too closely driven by the goal of maximizing shareholder value, rather than the health of the public. Unfortunately, many of the critics of the industry fail to understand the complexities of the industry and its role in the nation's healthcare system. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This is the second edition of a uniquely comprehensive and balanced discussion of pharmaceutical policy issues. All the chapters of the former edition have been fully re-written and extensively updated. In addition, the book includes six new chapters on emerging topics such as the broadened role of FDA regulations and the increasing diversity of the industry. An entire chapter is devoted to the biotechnology industry and one to alternative medicines, often called "nutraceuticals." Another new chapter discusses segments of the industry that specialize in particular activities including generic drugs and drug delivery systems. The recent controversial expansion of Medicare to cover outpatient drugs is discussed in depth. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industrie pharmaceutique / États-Unis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Médicaments / Politique gouvernementale / États-Unis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industrie pharmaceutique</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industry</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical policy</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Economics, Pharmaceutical / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Public Policy / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industrie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Wirtschaft</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical policy</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Internationaler Vergleich</subfield><subfield code="0">(DE-588)4120509-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelmarkt</subfield><subfield code="0">(DE-588)4003131-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Strukturwandel</subfield><subfield code="0">(DE-588)4058136-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelmarkt</subfield><subfield code="0">(DE-588)4003131-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">USA</subfield><subfield code="0">(DE-588)4078704-7</subfield><subfield code="D">g</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Strukturwandel</subfield><subfield code="0">(DE-588)4058136-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Pharmazeutische Industrie</subfield><subfield code="0">(DE-588)4045696-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Gesundheitspolitik</subfield><subfield code="0">(DE-588)4113743-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="2"><subfield code="a">Internationaler Vergleich</subfield><subfield code="0">(DE-588)4120509-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=191561</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBU</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">FLA_PDA_EBU</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028391275</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield></record></collection> |
| geographic | USA USA (DE-588)4078704-7 gnd |
| geographic_facet | USA |
| id | DE-604.BV042965407 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:13:57Z |
| institution | BVB |
| isbn | 9780199719747 0199719748 0195300955 9780195300956 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028391275 |
| oclc_num | 710992761 |
| open_access_boolean | |
| physical | 1 Online-Ressource (xiv, 336 pages) |
| psigel | ZDB-4-EBU FLA_PDA_EBU |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Oxford University Press |
| record_format | marc |
| spelling | Schweitzer, Stuart O. Verfasser aut Pharmaceutical economics and policy Stuart O. Schweitzer 2nd ed Oxford Oxford University Press 2007 1 Online-Ressource (xiv, 336 pages) txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index The pharmaceutical industry -- The biotechnology industry -- Other firms in the pharmaceutical industry -- Marketing pharmaceuticals -- The demand for pharmaceuticals -- Pharmaceutical prices -- The worldwide market for pharmaceuticals -- Pricing pharmaceuticals in a world environment -- The timing of drug approvals in the United States and abroad -- Pharmaceutical regulation and cost containment by the public sector -- Regulation by the private sector -- Pharmaceutical regulation in Europe -- Patent protection -- Evaluating New Drugs -- Complementary and alternative medicines -- Pharmaceuticals and health policy : a look ahead The pharmaceutical industry is praised as a world leader in high technology innovation and the creator of products that increase both longevity and quality of life for people throughout the world. At the same time, the industry is also criticized for its marketing and pricing practices and for its apparent anticompetitive responses to generic competition. Even its research and development priorities are criticized as being too closely driven by the goal of maximizing shareholder value, rather than the health of the public. Unfortunately, many of the critics of the industry fail to understand the complexities of the industry and its role in the nation's healthcare system. This book uses the tools of economic analysis to explore the conflicting priorities and aims of the pharmaceutical industry, from both an American and worldwide perspective. This is the second edition of a uniquely comprehensive and balanced discussion of pharmaceutical policy issues. All the chapters of the former edition have been fully re-written and extensively updated. In addition, the book includes six new chapters on emerging topics such as the broadened role of FDA regulations and the increasing diversity of the industry. An entire chapter is devoted to the biotechnology industry and one to alternative medicines, often called "nutraceuticals." Another new chapter discusses segments of the industry that specialize in particular activities including generic drugs and drug delivery systems. The recent controversial expansion of Medicare to cover outpatient drugs is discussed in depth. The introduction is also updated to address the volatile pace of pharmaceutical innovation and how the pharmaceutical industry has responded to the emergence of managed care Industrie pharmaceutique / États-Unis Médicaments / Politique gouvernementale / États-Unis Industrie pharmaceutique BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology bisacsh Pharmaceutical industry fast Pharmaceutical policy fast Economics, Pharmaceutical / United States Drug Industry / United States Public Policy / United States Industrie Wirtschaft Pharmaceutical industry United States Pharmaceutical policy United States Pharmaceutical industry Internationaler Vergleich (DE-588)4120509-1 gnd rswk-swf Pharmazeutische Industrie (DE-588)4045696-1 gnd rswk-swf Arzneimittelmarkt (DE-588)4003131-7 gnd rswk-swf Gesundheitspolitik (DE-588)4113743-7 gnd rswk-swf Strukturwandel (DE-588)4058136-6 gnd rswk-swf USA USA (DE-588)4078704-7 gnd rswk-swf USA (DE-588)4078704-7 g Arzneimittelmarkt (DE-588)4003131-7 s Gesundheitspolitik (DE-588)4113743-7 s 1\p DE-604 Pharmazeutische Industrie (DE-588)4045696-1 s Strukturwandel (DE-588)4058136-6 s 2\p DE-604 Internationaler Vergleich (DE-588)4120509-1 s 3\p DE-604 http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=191561 Aggregator Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Schweitzer, Stuart O. Pharmaceutical economics and policy Industrie pharmaceutique / États-Unis Médicaments / Politique gouvernementale / États-Unis Industrie pharmaceutique BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology bisacsh Pharmaceutical industry fast Pharmaceutical policy fast Economics, Pharmaceutical / United States Drug Industry / United States Public Policy / United States Industrie Wirtschaft Pharmaceutical industry United States Pharmaceutical policy United States Pharmaceutical industry Internationaler Vergleich (DE-588)4120509-1 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Arzneimittelmarkt (DE-588)4003131-7 gnd Gesundheitspolitik (DE-588)4113743-7 gnd Strukturwandel (DE-588)4058136-6 gnd |
| subject_GND | (DE-588)4120509-1 (DE-588)4045696-1 (DE-588)4003131-7 (DE-588)4113743-7 (DE-588)4058136-6 (DE-588)4078704-7 |
| title | Pharmaceutical economics and policy |
| title_auth | Pharmaceutical economics and policy |
| title_exact_search | Pharmaceutical economics and policy |
| title_full | Pharmaceutical economics and policy Stuart O. Schweitzer |
| title_fullStr | Pharmaceutical economics and policy Stuart O. Schweitzer |
| title_full_unstemmed | Pharmaceutical economics and policy Stuart O. Schweitzer |
| title_short | Pharmaceutical economics and policy |
| title_sort | pharmaceutical economics and policy |
| topic | Industrie pharmaceutique / États-Unis Médicaments / Politique gouvernementale / États-Unis Industrie pharmaceutique BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology bisacsh Pharmaceutical industry fast Pharmaceutical policy fast Economics, Pharmaceutical / United States Drug Industry / United States Public Policy / United States Industrie Wirtschaft Pharmaceutical industry United States Pharmaceutical policy United States Pharmaceutical industry Internationaler Vergleich (DE-588)4120509-1 gnd Pharmazeutische Industrie (DE-588)4045696-1 gnd Arzneimittelmarkt (DE-588)4003131-7 gnd Gesundheitspolitik (DE-588)4113743-7 gnd Strukturwandel (DE-588)4058136-6 gnd |
| topic_facet | Industrie pharmaceutique / États-Unis Médicaments / Politique gouvernementale / États-Unis Industrie pharmaceutique BUSINESS & ECONOMICS / Industries / Pharmaceutical & Biotechnology Pharmaceutical industry Pharmaceutical policy Economics, Pharmaceutical / United States Drug Industry / United States Public Policy / United States Industrie Wirtschaft Pharmaceutical industry United States Pharmaceutical policy United States Internationaler Vergleich Pharmazeutische Industrie Arzneimittelmarkt Gesundheitspolitik Strukturwandel USA |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=191561 |
| work_keys_str_mv | AT schweitzerstuarto pharmaceuticaleconomicsandpolicy |